Success Metrics

Clinical Success Rate
33.3%

Based on 2 completed trials

Completion Rate
33%(2/6)
Active Trials
0(0%)
Results Posted
250%(5 trials)
Terminated
4(67%)

Phase Distribution

Ph phase_2
4
67%
Ph phase_3
1
17%
Ph phase_1
1
17%

Phase Distribution

1

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

2 of 6 finished

Non-Completion Rate

66.7%

4 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(2)
Terminated(4)

Detailed Status

Terminated4
Completed2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 24 (66.7%)
Phase 31 (16.7%)

Trials by Status

completed233%
terminated467%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_3

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

NCT02312206
terminatedphase_2

Renal AL Amyloid Involvement and NEOD001

NCT03168906
terminatedphase_2

Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

NCT02613182
completedphase_2

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

NCT02632786
terminatedphase_2

Study in Subjects With Light Chain (AL) Amyloidosis

NCT03154047
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02312206Phase 3

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

Terminated
NCT03168906Phase 2

Renal AL Amyloid Involvement and NEOD001

Terminated
NCT02613182Phase 2

Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Terminated
NCT02632786Phase 2

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

Completed
NCT03154047Phase 2

Study in Subjects With Light Chain (AL) Amyloidosis

Terminated
NCT01707264Phase 1

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6